-
October 6, 2021 Interview with James Lanthier, CEO of Mindset PharmaIn our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when...
-
October 5, 2021 Interview with Ian McDonald, CEO & Director of Bright Minds BiosciencesIn this wide ranging interview many topics are covered, starting with the philosophy and vision...
-
October 5, 2021 Meet Bright Minds: The NEXT GEN Psychedelics Company Tackling Pain, Depression and MORE (DRUG/BMBIF)In today’s episode of the Psychedelic Spotlight Podcast, James Hallifax from the Psychedelic Investor YouTube...
-
October 1, 2021 Psychedelic Business Spotlight: October 1, 2021This week in psychedelic business news: more evidence supporting ketamine for depression; a new use...
-
September 28, 2021 Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity EpidemicThe psychedelic bioscience company's top advisor tells Psychedelic Spotlight that psilocybin "affects at least the...
-
September 27, 2021 Mind Cure Health Targeting Hypoactive Sexual Desire Disorder with MDMA“Women’s desire issues have not been adequately addressed to date, and we believe this treatment...
-
September 26, 2021 MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studiesMindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED's Psilocybin and LSD...
-
September 24, 2021 Interview with Trevor Millar, Advisor, NeonMind BiosciencesIn our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based...
-
September 24, 2021 How Cybin Is ‘Revolutionizing’ Mental Healthcare with Novel Psychedelic CompoundsCEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions...
-
September 24, 2021 Psychedelic Business Spotlight: September 24, 2021This week in psychedelic business news: two patents may revolutionize the medical application of psychedelic...
